Nanjing Hicin Pharmaceutical Co., Ltd. (SHE:300584)
China · Delayed Price · Currency is CNY 44.00
-0.44 (-0.99%)
Feb 4, 2026, 1:15 PM CST
SHE:300584 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 613.14 | 502.11 | 515.98 | 522.73 | 570.8 | 704.09 |
Other Revenue | 2.25 | 2.25 | 1.85 | 3.73 | 7.52 | 2.21 |
| 615.39 | 504.36 | 517.83 | 526.47 | 578.32 | 706.3 | |
Revenue Growth (YoY) | 22.98% | -2.60% | -1.64% | -8.97% | -18.12% | -23.61% |
Cost of Revenue | 110.53 | 93.07 | 101.28 | 133.79 | 109.93 | 174.61 |
Gross Profit | 504.86 | 411.29 | 416.56 | 392.68 | 468.39 | 531.69 |
Selling, General & Admin | 395.81 | 309.65 | 313.51 | 325.99 | 403.48 | 422.13 |
Research & Development | 37.21 | 40.28 | 46.63 | 18.22 | 21.7 | 31.88 |
Other Operating Expenses | 12.05 | 9.8 | 8.81 | 9.77 | 12.48 | 12.38 |
Operating Expenses | 443.97 | 358.89 | 370.61 | 358.05 | 438.98 | 466.09 |
Operating Income | 60.89 | 52.4 | 45.94 | 34.63 | 29.41 | 65.59 |
Interest Expense | -7.09 | -8.98 | -8.27 | -7.25 | -7.5 | -7.01 |
Interest & Investment Income | 0.07 | 0.12 | 0.96 | 1.02 | 0.78 | 0.51 |
Currency Exchange Gain (Loss) | -0.01 | -0.01 | 0.02 | 0.01 | -0.06 | 0.01 |
Other Non Operating Income (Expenses) | 1.04 | -0.23 | -0.09 | -0.54 | -0.02 | -0.03 |
EBT Excluding Unusual Items | 54.91 | 43.3 | 38.56 | 27.86 | 22.61 | 59.07 |
Gain (Loss) on Sale of Investments | -2.65 | - | 0.04 | 0.93 | 306.31 | 0.08 |
Gain (Loss) on Sale of Assets | 0.03 | - | -0.79 | -0.95 | -0.02 | -0.07 |
Asset Writedown | -9.92 | -2.09 | -0.04 | -0.92 | -0.29 | -0.92 |
Other Unusual Items | 3.29 | -0.19 | -0.08 | 1.86 | 1.83 | 3.19 |
Pretax Income | 45.67 | 41.03 | 37.69 | 28.78 | 330.45 | 61.35 |
Income Tax Expense | 1.43 | 0.87 | 1.37 | -3.35 | 45.61 | 6.82 |
Earnings From Continuing Operations | 44.24 | 40.16 | 36.32 | 32.12 | 284.83 | 54.53 |
Minority Interest in Earnings | 0.54 | 0.05 | - | 0.32 | 1.05 | 0.7 |
Net Income | 44.78 | 40.22 | 36.32 | 32.45 | 285.88 | 55.23 |
Net Income to Common | 44.78 | 40.22 | 36.32 | 32.45 | 285.88 | 55.23 |
Net Income Growth | 6.59% | 10.75% | 11.92% | -88.65% | 417.61% | -43.21% |
Shares Outstanding (Basic) | 120 | 120 | 120 | 120 | 120 | 120 |
Shares Outstanding (Diluted) | 120 | 120 | 120 | 120 | 120 | 120 |
Shares Change (YoY) | -0.01% | 0.01% | 0.01% | 0.00% | 0.01% | -0.01% |
EPS (Basic) | 0.37 | 0.34 | 0.30 | 0.27 | 2.38 | 0.46 |
EPS (Diluted) | 0.37 | 0.34 | 0.30 | 0.27 | 2.38 | 0.46 |
EPS Growth | 6.61% | 10.74% | 11.91% | -88.65% | 417.55% | -43.21% |
Free Cash Flow | -0.98 | -17.98 | -173.29 | -224.76 | -34.47 | -46.71 |
Free Cash Flow Per Share | -0.01 | -0.15 | -1.44 | -1.87 | -0.29 | -0.39 |
Dividend Per Share | 0.100 | 0.100 | 0.050 | - | 0.250 | 0.125 |
Dividend Growth | 100.00% | 100.00% | - | - | 100.00% | -50.00% |
Gross Margin | 82.04% | 81.55% | 80.44% | 74.59% | 80.99% | 75.28% |
Operating Margin | 9.89% | 10.39% | 8.87% | 6.58% | 5.09% | 9.29% |
Profit Margin | 7.28% | 7.97% | 7.01% | 6.16% | 49.43% | 7.82% |
Free Cash Flow Margin | -0.16% | -3.56% | -33.46% | -42.69% | -5.96% | -6.61% |
EBITDA | 113.21 | 105.25 | 99.49 | 82.69 | 66.41 | 97.14 |
EBITDA Margin | 18.40% | 20.87% | 19.21% | 15.71% | 11.48% | 13.75% |
D&A For EBITDA | 52.32 | 52.85 | 53.55 | 48.07 | 37 | 31.55 |
EBIT | 60.89 | 52.4 | 45.94 | 34.63 | 29.41 | 65.59 |
EBIT Margin | 9.89% | 10.39% | 8.87% | 6.58% | 5.09% | 9.29% |
Effective Tax Rate | 3.13% | 2.11% | 3.65% | - | 13.80% | 11.12% |
Revenue as Reported | 615.39 | 504.36 | 517.83 | 526.47 | 578.32 | 706.3 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.